ProShare Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $681K | Sell |
88,769
-8,671
| -9% | -$59.4K | ﹤0.01% | 913 |
|
|
2025
Q4 | $193K | Buy |
97,440
+24,434
| +33% | +$55.4K | ﹤0.01% | 1738 |
|
|
2025
Q3 | $180K | Sell |
73,006
-7,122
| -9% | -$18.3K | ﹤0.01% | 1718 |
|
|
2025
Q2 | $212K | Buy |
80,128
+14,105
| +21% | +$37.9K | ﹤0.01% | 1689 |
|
|
2025
Q1 | $199K | Sell |
66,023
-7,750
| -11% | -$23.5K | ﹤0.01% | 1691 |
|
|
2024
Q4 | $189K | Buy |
73,773
+5,261
| +8% | +$21.9K | ﹤0.01% | 1902 |
|
|
2024
Q3 | $255K | Buy |
68,512
+8,059
| +13% | +$37.3K | ﹤0.01% | 1578 |
|
|
2024
Q2 | $382K | Sell |
60,453
-10,160
| -14% | -$67K | ﹤0.01% | 1132 |
|
|
2024
Q1 | $379K | Buy |
70,613
+6,004
| +9% | +$27.2K | ﹤0.01% | 1263 |
|
|
2023
Q4 | $324K | Buy |
64,609
+19,981
| +45% | +$62.7K | ﹤0.01% | 1316 |
|
|
2023
Q3 | $75.4K | Buy |
44,628
+2,080
| +5% | +$4.18K | ﹤0.01% | 1677 |
|
|
2023
Q2 | $118K | Buy |
42,548
+4,185
| +11% | +$11.8K | ﹤0.01% | 1670 |
|
|
2023
Q1 | $69.8K | Sell |
38,363
-5,278
| -12% | -$16.4K | ﹤0.01% | 1639 |
|
|
2022
Q4 | $221K | Buy |
43,641
+944
| +2% | +$5.18K | ﹤0.01% | 1430 |
|
|
2022
Q3 | $212K | Buy |
42,697
+2,510
| +6% | +$11.4K | ﹤0.01% | 1367 |
|
|
2022
Q2 | $150K | Sell |
40,187
-14,004
| -26% | -$56.2K | ﹤0.01% | 1540 |
|
|
2022
Q1 | $304K | Sell |
54,191
-16,719
| -24% | -$103K | ﹤0.01% | 1621 |
|
|
2021
Q4 | $431K | Sell |
70,910
-21,404
| -23% | -$161K | ﹤0.01% | 1560 |
|
|
2021
Q3 | $899K | Buy |
92,314
+5,983
| +7% | +$65.8K | ﹤0.01% | 939 |
|
|
2021
Q2 | $1.23M | Buy |
86,331
+62,807
| +267% | +$1.04M | ﹤0.01% | 919 |
|
|
2021
Q1 | $558K | Sell |
23,524
-213
| -0.9% | -$5.52K | ﹤0.01% | 1359 |
|
|
2020
Q4 | $316K | Buy |
+23,737
| New | +$228K | ﹤0.01% | 1578 |
|
|
2018
Q4 | – | Sell |
-35,750
| Closed | -$132K | – | 1632 |
|
|
2018
Q3 | $132K | Sell |
35,750
-730
| -2% | -$2.31K | ﹤0.01% | 1656 |
|
|
2018
Q2 | $112K | Sell |
36,480
-4,032
| -10% | -$14.9K | ﹤0.01% | 1696 |
|
|
2018
Q1 | $158K | Sell |
40,512
-6,677
| -14% | -$29.3K | ﹤0.01% | 1582 |
|
|
2017
Q4 | $212K | Buy |
47,189
+345
| +0.7% | +$1.63K | ﹤0.01% | 1612 |
|
|
2017
Q3 | $257K | Buy |
46,844
+1,975
| +4% | +$12.2K | ﹤0.01% | 1197 |
|
|
2017
Q2 | $341K | Sell |
44,869
-1,016
| -2% | -$4.39K | ﹤0.01% | 1105 |
|
|
2017
Q1 | $163K | Sell |
45,885
-11,214
| -20% | -$55.4K | ﹤0.01% | 1475 |
|
|
2016
Q4 | $327K | Buy |
57,099
+3,555
| +7% | +$23.7K | ﹤0.01% | 1308 |
|
|
2016
Q3 | $417K | Sell |
53,544
-9,519
| -15% | -$71.1K | 0.01% | 1023 |
|
|
2016
Q2 | $392K | Buy |
63,063
+2,137
| +4% | +$16.6K | 0.01% | 1073 |
|
|
2016
Q1 | $501K | Sell |
60,926
-5,356
| -8% | -$50.5K | 0.01% | 989 |
|
|
2015
Q4 | $1.15M | Buy |
+66,282
| New | +$983K | 0.01% | 683 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
ProShare Advisors's IBRX Position: Q1 2026 in Review
ProShare Advisors reduced its ImmunityBio (IBRX) stake by 8.9% in Q1 2026, selling an estimated $59.4K and leaving 88,769 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #913.
ProShare Advisors first reported a position in IBRX in Q4 2015 and has held it in 34 quarters since. The position peaked at $1.23M in Q2 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- ProShare Advisors held 88,769 shares of ImmunityBio worth $681K as of Q1 2026.
- ProShare Advisors sold 8,671 ImmunityBio shares in Q1 2026, an estimated $59.4K.
- ImmunityBio made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #913 holding.
- ProShare Advisors first reported a position in ImmunityBio in Q4 2015 and has held it in 34 quarters since.
- ProShare Advisors's ImmunityBio position peaked at $1.23M in Q2 2021.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.